Q4 2024 Management View CEO Vas Narasimhan highlighted Novartis' strong performance in Q4 2024, with sales increasing 16% and ...

Good morning and good afternoon, and welcome to the Novartis Q4 2024 results release conference call and live webcast.

Novartis has finally given up on iscalimab after deciding that the anti-CD40 antibody is not worth pursuing in Sjögren’s ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bisepcifics ...

Novartis reported strong Q4 earnings and sales growth, with CEO Narasimhan reportedly downplaying concerns over Entresto's ...

Swiss drug-major Novartis AG reported Friday weak net earnings in its fourth quarter on the absence of prior year's significant gain ...

Swiss pharmaceutical giant Novartis (NVS) on Friday reported forecast-beating quarterly sales as its clutch of heart failure to breast cancer ...

Swiss pharmaceutical giant Novartis on Friday reported fourth-quarter results after repeatedly raising its full-year guidance ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.

DelveInsight’s c-MET-NSCLC pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline ...